Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

BACKGROUND AND AIMS: Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities. However, unfortunately, treatment failure still occurs in about 5–15% of patients treated with DAA‐based combination reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Abo-amer, Yousry Esam-Eldin, Badawi, Rehab, El-Abgeegy, Mohamed, Elsergany, Heba Fadl, Mohamed, Ahmed Abdelhaleem, Mostafa, Sahar Mohamed, Alegaily, Hatem Samir, Soliman, Shaimaa, Elnawasany, Sally, Abd-Elsalam, Sherief
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396033/
https://www.ncbi.nlm.nih.gov/pubmed/32774374
http://dx.doi.org/10.1155/2020/9075905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396033/
https://www.ncbi.nlm.nih.gov/pubmed/32774374
http://dx.doi.org/10.1155/2020/9075905

Ejemplares similares